1. Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54.
2. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–93.
3. Regeneron Pharmaceuticals. Regeneron's REGEN-COV2 is first antibody cocktail for COVID-19 to receive FDA emergency use authorization [media release]. 21 Nov 2020. http://www.regeneron.com.
4. Regeneron Pharmaceuticals Inc. Securities and Exchange Commission: Form 10-Q. 2021. https://investor.regeneron.com/static-files/7da40791-c1e0-4d9b-9edf-3ca9768f52a8. Accessed 13 Sept 2021.
5. European Medicines Agency. EMA issues advice on use of REGN-COV2 antibody combination (casirivimab/imdevimab) [media release]. 26 Feb 2021. https://www.ema.europa.eu/en/news/ema-issues-advice-use-regn-cov2-antibody-combination-casirivimab-imdevimab.